References
1.Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for
the Management of Patients with Atrial Fibrillation: a report of the
American College of Cardiology/American Heart Association Task Force on
Practice Guidelines and the European Society of Cardiology Committee for
Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for
the Management of Patients With Atrial Fibrillation): developed in
collaboration with the European Heart Rhythm Association and the Heart
Rhythm Society. Circulation . 2006;114:e257-354.
2.Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the
management of atrial fibrillation developed in collaboration with EACTS.European journal of cardio-thoracic surgery : official journal of
the European Association for Cardio-thoracic Surgery . 2016;50:e1-e88.
3.Healey JS, Parkash R, Pollak T, et al. Canadian Cardiovascular Society
atrial fibrillation guidelines 2010: etiology and initial
investigations. The Canadian journal of cardiology .
2011;27:31-37.
4.January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for
the management of patients with atrial fibrillation: a report of the
American College of Cardiology/American Heart Association Task Force on
practice guidelines and the Heart Rhythm Society. Circulation .
2014;130:e199-267.
5.Jackson SL, Tong X, Yin X, et al. Emergency Department, Hospital
Inpatient, and Mortality Burden of Atrial Fibrillation in the United
States, 2006 to 2014. The American journal of cardiology .
2017;120:1966-1973.
6.DeWilde S, Carey IM, Emmas C, et al. Trends in the prevalence of
diagnosed atrial fibrillation, its treatment with anticoagulation and
predictors of such treatment in UK primary care. Heart .
2006;92:1064-1070.
7.Chen S, Weise FK, Chun KRJ, et al. Antithrombotic strategies after
interventional left atrial appendage closure: an update. Expert
review of cardiovascular therapy . 2018;16:675-678.
8.Tilz RR, Potpara T, Chen J, et al. Left atrial appendage occluder
implantation in Europe: indications and anticoagulation
post-implantation. Results of the European Heart Rhythm Association
Survey. Europace . 2017;19:1737-1742.
9.Holmes DR, Jr., Kar S, Price MJ, et al. Prospective randomized
evaluation of the Watchman Left Atrial Appendage Closure device in
patients with atrial fibrillation versus long-term warfarin therapy: the
PREVAIL trial. J Am Coll Cardiol . 2014;64:1-12.
10.Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left
atrial appendage versus warfarin therapy for prevention of stroke in
patients with atrial fibrillation: a randomised non-inferiority trial.Lancet . 2009;374:534-542.
11.Sondergaard L, Wong YH, Reddy VY, et al. Propensity-Matched
Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After
Left Atrial Appendage Closure With WATCHMAN. JACC Cardiovasc
Interv . 2019;12:1055-1063.
12.Bergmann MW, Ince H, Kische S, et al. Real-world safety and efficacy
of WATCHMAN LAA closure at one year in patients on dual antiplatelet
therapy: results of the DAPT subgroup from the EWOLUTION all-comers
study. EuroIntervention . 2018;13:2003-2011.
13.Weise FK, Bordignon S, Perrotta L, et al. Short-term dual
antiplatelet therapy after interventional left atrial appendage closure
with different devices. EuroIntervention . 2018;13:e2138-e2146.
14.Bergmann MW, Betts TR, Sievert H, et al. Safety and efficacy of early
anticoagulation drug regimens after WATCHMAN left atrial appendage
closure: three-month data from the EWOLUTION prospective, multicentre,
monitored international WATCHMAN LAA closure registry.EuroIntervention . 2017;13:877-884.
15.Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the
management of atrial fibrillation developed in collaboration with EACTS.Eur Heart J . 2016;37:2893-2962.
16.Meier B, Blaauw Y, Khattab AA, et al. EHRA/EAPCI expert consensus
statement on catheter-based left atrial appendage occlusion.Europace . 2014;16:1397-1416.
17.Fountain RB, Holmes DR, Chandrasekaran K, et al. The PROTECT AF
(WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in
Patients with Atrial Fibrillation) trial. Am Heart J .
2006;151:956-961.
18.Tzikas A, Holmes DR, Jr., Gafoor S, et al. Percutaneous left atrial
appendage occlusion: the Munich consensus document on definitions,
endpoints and data collection requirements for clinical studies.EuroIntervention . 2016;12:103-111.
19.Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions
for cardiovascular clinical trials: a consensus report from the Bleeding
Academic Research Consortium. Circulation . 2011;123:2736-2747.
20.Kaatz S, Ahmad D, Spyropoulos AC, et al. Definition of clinically
relevant non-major bleeding in studies of anticoagulants in atrial
fibrillation and venous thromboembolic disease in non-surgical patients:
communication from the SSC of the ISTH. J Thromb Haemost .
2015;13:2119-2126.
21.Kappetein AP, Head SJ, Genereux P, et al. Updated standardized
endpoint definitions for transcatheter aortic valve implantation: the
Valve Academic Research Consortium-2 consensus document.EuroIntervention . 2012;8:782-795.
22.Hicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and
stroke endpoint definitions for clinical trials. J Am Coll
Cardiol . 2018;71:1021-1034.
23.Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification
schemes for ischaemic stroke and bleeding in 182 678 patients with
atrial fibrillation: the Swedish Atrial Fibrillation cohort study.Eur Heart J . 2012;33:1500-1510.
24.Lip GY, Frison L, Halperin JL, et al. Comparative validation of a
novel risk score for predicting bleeding risk in anticoagulated patients
with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal
Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile
INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll
Cardiol . 2011;57:173-180.
25.Maarse M, Swaans MJ, Boersma LVA. Postprocedural Management:
Anticoagulation and Beyond. Card Electrophysiol Clin .
2020;12:77-88.
26.Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage
closure with the Watchman device in patients with a contraindication for
oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With
Watchman Left Atrial Appendage Closure Technology). J Am Coll
Cardiol . 2013;61:2551-2556.
27.Korsholm K, Nielsen KM, Jensen JM, et al. Transcatheter left atrial
appendage occlusion in patients with atrial fibrillation and a high
bleeding risk using aspirin alone for post-implant antithrombotic
therapy. EuroIntervention . 2017;12:2075-2082.
28.Jalal Z, Dinet ML, Combes N, et al. Percutaneous left atrial
appendage closure followed by single antiplatelet therapy: Short- and
mid-term outcomes. Arch Cardiovasc Dis . 2017;110:242-249.
29.Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial
Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am
Coll Cardiol . 2017;70:2964-2975.
30.Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left
atrial appendage closure: results from the Watchman Left Atrial
Appendage System for Embolic Protection in Patients with AF (PROTECT AF)
clinical trial and the Continued Access Registry. Circulation .
2011;123:417-424.
31.Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of
left atrial appendage closure with the WATCHMAN device: peri-procedural
outcomes from the EWOLUTION registry. Eur Heart J .
2016;37:2465-2474.
32.Saw J, Tzikas A, Shakir S, et al. Incidence and Clinical Impact of
Device-Associated Thrombus and Peri-Device Leak Following Left Atrial
Appendage Closure With the Amplatzer Cardiac Plug. JACC Cardiovasc
Interv . 2017;10:391-399.
33.Pracon R, Bangalore S, Dzielinska Z, et al. Device Thrombosis After
Percutaneous Left Atrial Appendage Occlusion Is Related to Patient and
Procedural Characteristics but Not to Duration of Postimplantation Dual
Antiplatelet Therapy. Circ Cardiovasc Interv . 2018;11:e005997.
34.Fauchier L, Cinaud A, Brigadeau F, et al. Device-related thrombosis
after percutaneous left atrial appendage ccclusion for atrial
fibrillation. J Am Coll Cardiol . 2018;71:1528-1536.
Table 1. Baseline characteristics